NovoSculpt Named Best Body Contouring Clinic in the Tri-State Area for 2025

NovoSculpt has been honored as the Best Body Contouring Clinic in the Tri-State Area for 2025, solidifying its place as a leader in aesthetic care and body sculpting services.
Greenwich, CT, USA, June 15, 2025 -- NovoSculpt Celebrates Prestigious Recognition in Body Contouring Excellence
NovoSculpt proudly announces its recognition as the Best Body Contouring Clinic in the Tri-State Area for 2025, a prestigious title that highlights the clinic's leadership in the rapidly growing field of body sculpting. The award emphasizes NovoSculpt's unwavering commitment to providing safe, effective, and customized solutions for those seeking transformative aesthetic results.
The recognition celebrates the clinic's dedication to patient care, innovative treatments, and personalized experiences, solidifying its position as the premier destination for body contouring in the region. NovoSculpt's approach to aesthetic medicine continues to disrupt traditional methods by focusing on minimally invasive treatments that provide lasting and natural results.
A Cutting-Edge Approach to Minimally Invasive Fat Removal
At the heart of NovoSculpt's success is its groundbreaking minimally invasive fat removal procedure, which allows patients to remove up to 11 pounds of localized fat in a single session. This innovative technique eliminates the need for scalpels, stitches, or general anesthesia, providing a safe and efficient solution for body sculpting. The procedure ensures a quick recovery time, with many patients resuming their daily activities in as little as 24 hours.
NovoSculpt's approach has proven to be a highly effective and patient-friendly alternative to traditional body contouring surgeries, enabling clients to achieve their desired body shape with minimal discomfort and downtime. This cutting-edge method continues to set NovoSculpt apart from other clinics in the Tri-State Area and positions the clinic as a trailblazer in the aesthetic industry.
Led by Expertise: Roberto Magana and a Skilled Team
NovoSculpt's success is driven by the vision and leadership of its founder and CEO, Roberto Magana, MBA. With over 15 years of experience in business strategy and leadership, Roberto's guidance has been pivotal in shaping the clinic's operations and ensuring the highest standards of care. Under his leadership, NovoSculpt has assembled a highly skilled team of medical professionals, including elite plastic surgeons and experienced staff, all of whom are dedicated to delivering exceptional results for every patient.
Roberto's commitment to operational excellence and patient satisfaction has been integral to the clinic's rapid growth and its recognition as the top body contouring clinic in the region. The clinic's collaboration with top-tier medical personnel ensures that each patient receives comprehensive care, with personalized treatment plans designed to meet their unique goals.
Building Trust with Transparent and Safe Practices
NovoSculpt's reputation is built on trust, transparency, and an unwavering focus on safety. The clinic operates within a QuadA-certified surgical suite, ensuring that every procedure is conducted in a safe and controlled environment. This certification is a reflection of the clinic's commitment to adhering to the highest medical and safety standards, providing clients with peace of mind throughout their body sculpting journey.
By prioritizing patient safety and comfort, NovoSculpt has earned a loyal clientele who often return to enhance additional areas or recommend the clinic to others—confident in its ability to deliver authentic, natural-looking results in a single session. The clinic's client-first approach has fostered strong, lasting relationships with patients, many of whom experience meaningful boosts in confidence and overall well-being.
Patient Satisfaction and Proven Results
NovoSculpt's minimally invasive approach consistently results in high patient satisfaction, with many clients experiencing impressive, natural-looking results after just one session. The clinic's innovative fat removal procedure has become the preferred choice for those seeking to reshape their bodies without undergoing more invasive surgical procedures.
In addition to fat removal, NovoSculpt offers a range of aesthetic treatments, including skin tightening with NovoTight™ and fat transfer for sculpted curves. These services are customized to each patient's specific needs, ensuring that every treatment plan aligns with their personal aesthetic vision. This personalized approach has contributed to NovoSculpt's reputation for excellence and its status as the top body contouring clinic in the Tri-State Area.
A Vision of Innovation and Care
NovoSculpt's success story is one of innovation, care, and patient-centric solutions. Founded by Roberto Magana, the clinic was created with the goal of offering a minimally invasive, highly effective approach to body contouring. Roberto's vision has led to the development of a clinic that fills the gaps in the market for minimally invasive, customized body sculpting treatments that deliver lasting results.
As the clinic continues to innovate and grow, NovoSculpt's commitment to patient satisfaction and exceptional care remains at the forefront. The clinic's ability to adapt to changing industry trends while maintaining its focus on personalized, safe, and effective treatments has allowed it to remain a leader in the body contouring field.
Celebrating Success: The 2025 Recognition
NovoSculpt's recognition as the Best Body Contouring Clinic in the Tri-State Area for 2025 is a monumental achievement that celebrates the clinic's leadership, innovation, and dedication to its patients. This award reaffirms NovoSculpt's position as a disruptor in the body contouring industry, offering cutting-edge treatments that prioritize both safety and transformative results.
As the clinic looks toward the future, it remains committed to setting the standard for excellence in aesthetic medicine. With a growing reputation for delivering remarkable body sculpting results, NovoSculpt continues to reshape the way individuals approach body contouring and aesthetic care.
About NovoSculpt
NovoSculpt is a leading body contouring clinic based in Greenwich, Connecticut, specializing in minimally invasive targeted fat removal, precision skin tightening, and aesthetic fat transfers—all performed to enhance body contours with immediate, visible results after a single session. No repeat treatments are necessary. Serving clients across the Tri-State Area and beyond, the clinic offers personalized body sculpting solutions tailored to each patient's goals. Founded by Roberto Magana, MBA, NovoSculpt combines cutting-edge technology, a skilled medical team, and a patient-centered approach to deliver safe, effective, and lasting results—without the need for traditional surgery.
Media Contact
Roberto Magana, MBA
Founder & CEO, NovoSculpt
Website: https://novosculpt.us
Email: [email protected]
Instagram: @novosculptus
Facebook: @NovoSculpt
TikTok: @novosculptus
LinkedIn: NovoSculpt
Contact Info:
Name: Roberto Magana
Email: Send Email
Organization: NovoSculpt
Website: https://novosculpt.us
Release ID: 89162338
If you encounter any issues, discrepancies, or concerns regarding the content provided in this press release, or if there is a need for a press release takedown, we urge you to notify us without delay at [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our expert team will be available to promptly respond within 8 hours – ensuring swift resolution of identified issues or offering guidance on removal procedures. Delivering accurate and reliable information is fundamental to our mission.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

an hour ago

• Yahoo

Abvance Therapeutics Announces Presentation of Human Clinical Data at the 85th Scientific Sessions of the American Diabetes Association

CHICAGO, June 21, 2025 (GLOBE NEWSWIRE) -- Abvance Therapeutics, a biotechnology company developing next generation glucagon analogs and therapies to prevent hypoglycemia and improve glucose management, today announced the presentation of new human clinical data at the 85th Scientific Sessions of the American Diabetes Association (ADA), held in Chicago. The poster, titled 'Uncovering the bidirectional glucose-dependent relationship of insulin and glucagon: a meal-challenge study in patients with Type 1 diabetes,' was presented by Dr. Guillaume Kraft, Research Assistant Professor at Vanderbilt University. The study examined how insulin and glucagon behave when delivered together in a fixed ratio at mealtime in people with Type 1 diabetes. The study builds on earlier preclinical research at Vanderbilt University, where scientists observed that insulin and glucagon might interact differently depending on a person's blood sugar level. In that work, the hormones appeared to shift in dominance—insulin having a stronger effect when glucose was high, and glucagon becoming more influential when glucose was low. This human study explored whether similar patterns could be seen when the two hormones were given together in a single fixed ratio at mealtime to people with Type 1 diabetes, under closely monitored conditions. The clinical trial was led by Dr. Bruce Bode and his team at Atlanta Diabetes Associates involving 15 participants with Type 1 diabetes. The results suggested that combining glucagon with insulin at a single fixed ratio at mealtime may offer protection against hypoglycemia during the post-meal drop in blood sugar—without interfering with key metabolic processes. The combination was well tolerated and showed a favorable safety profile. 'We are grateful to Dr. Kraft and the research team at Vanderbilt, and to Dr. Bode and his team in Atlanta, for advancing this important translational work,' said Dr. David Maggs, co-founder of Abvance Therapeutics. 'This study provides early human insight into how carefully designed glucagon-insulin combinations may offer a new tool for improving the day-to-day safety of intensive insulin therapy.' The results mark the first human data evaluating fixed-ratio co-administration of insulin and glucagon in a mealtime setting and offer early support for Abvance's approach to rationally engineered glucagon analogs. 'Abvance is excited to build on this foundational work as we advance our pipeline of glucagon-based therapies designed to integrate seamlessly into real-world treatment strategies,' added Maggs. About Abvance TherapeuticsAbvance Therapeutics, Inc. is a privately held biotechnology company advancing novel glucagon-based therapies designed to integrate into the lived experience of diabetes care. Founded on research from Vanderbilt University and led by a team with expertise in diabetes therapeutics, drug development, and health technology. For more information visit Media & Investor ContactsEdward Raskined@ Veena Raoveena@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Yahoo

2 hours ago

• Yahoo

UnitedHealth Group (NYSE:UNH) Announces Debt Financing Totalling US$3 Billion

UnitedHealth Group recently completed a substantial debt financing deal, raising $3 billion through the issuance of various Notes. This move comes amid a period of legal settlements, such as the $69 million ERISA case, and operational restructuring, including exploring bids for its Latin American operations. Despite these significant developments, the company's stock price remained relatively flat over the last month, reflecting broader market trends which also showed minimal movement. The dividend increase and shareholder discussions on executive compensation may have subtly influenced sentiment, but overall, these events seemed to align with the market's flat performance. UnitedHealth Group has 1 possible red flag we think you should know about. Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit. UnitedHealth Group's recent $3 billion debt financing and restructuring efforts, such as evaluating bids for its Latin American operations, are significant developments. While the near-term stock price remained relatively stable amid these changes, over the past five years, the company's total shareholder return, including dividends, was 13.61%. This reflects a steady growth trajectory, although in the last year, UnitedHealth underperformed the US Healthcare industry. The current share price sees a slight discount from the analyst consensus price target of $547.65, which is 28% higher than the present value. Despite recent legal settlements and compensation discussions, the company's aggressive push towards digital tools and Medicare adjustments might bolster future earnings and revenue. UnitedHealth's projected earnings per share and revenue growth is positioned slightly behind broader market expectations over the next few years, yet planned improvements in operational efficiencies could bridge this gap over time. Learn about UnitedHealth Group's future growth trajectory here. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:UNH. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Washington Post

2 hours ago

• Washington Post

New insight into Texas family detention reveals adults fighting kids for clean water

McALLEN, Texas — Adults fighting kids for clean water, despondent toddlers and a child with swollen feet denied a medical exam — these first-hand accounts from immigrant families at detention centers included in a motion filed by advocates Friday night are offering a glimpse of conditions at Texas facilities. Families shared their testimonies with immigrant advocates filing a lawsuit to prevent the Trump administration from terminating the Flores Settlement Agreement, a '90s-era policy that requires immigrant children detained in federal custody be held in safe and sanitary conditions.